Company research
Oruka Therapeutics, Inc.
CIK 907654Updated Nov 14, 2026
SecurityORKA · NASDAQ · equity
Name history
ARCA biopharma, Inc. · through Aug 30, 2024NUVELO INC · through Jan 27, 2009HYSEQ INC · through Jan 28, 2003
ORKA price & chart
Loading TradingView…
NASDAQ:ORKA on TradingView ↗About the company
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
In the news
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer ↗
Seeking Alpha
Oruka Therapeutics GAAP EPS of -$0.63 in-line ↗
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis - Slideshow ↗
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript ↗
SEC disclosures
Oruka Therapeutics, Inc. IPO declared effective by SEC ↗
Recent filings
10-Q filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
144 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 509,251,000Source | 414,090,000Source | 1,139,394,000Source | 357,418,000Source | 33,844,000Source | 504,480,000Source | 377,112,000Source | 36,706,000Source | 488,617,000Source | 396,019,000Source | 37,861,000Source | 43,085,000Source |
| Property, Plant and Equipment, NetUSD | 253,000Source | 160,000Source | 275,000Source | 174,000Source | 4,000Source | 318,000Source | 159,000Source | 7,000Source | 288,000Source | 162,000Source | 10,000Source | 25,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 91,253,000Source | 410,875,000Source | 268,470,000Source | 65,396,000Source | 33,283,000Source | 49,520,000Source | 83,572,000Source | 35,903,000Source | 46,935,000Source | 61,575,000Source | 37,431,000Source | 42,445,000Source |
| Assets, CurrentUSD | 355,163,000Source | 412,949,000Source | 884,559,000Source | 332,012,000Source | 33,820,000Source | 395,249,000Source | 352,083,000Source | 36,670,000Source | 343,857,000Source | 376,869,000Source | 37,592,000Source | 42,699,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,008,000Source | 2,074,000Source | 10,995,000Source | 3,606,000Source | — | 6,420,000Source | 2,989,000Source | — | 6,813,000Source | 1,221,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 1,969,000Source | 938,000Source | 2,415,000Source | 2,076,000Source | 8,000Source | 1,687,000Source | 814,000Source | 17,000Source | 1,830,000Source | 876,000Source | 247,000Source | 343,000Source |
| Other Assets, NoncurrentUSD | 103,000Source | 43,000Source | 128,000Source | 103,000Source | 12,000Source | 103,000Source | 103,000Source | 12,000Source | 103,000Source | 43,000Source | 12,000Source | 18,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 22,460,000Source | 18,881,000Source | 24,845,000Source | 13,776,000Source | 1,271,000Source | 17,760,000Source | 12,387,000Source | 1,581,000Source | 16,687,000Source | 13,798,000Source | 841,000Source | 1,412,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 48,000Source | 35,000Source | 61,000Source | 37,000Source | 14,000Source | 50,000Source | 37,000Source | 14,000Source | 49,000Source | 37,000Source | 14,000Source | 14,000Source |
| Additional Paid in CapitalUSD | 643,201,000Source | 397,345,000Source | 1,375,443,000Source | 469,998,000Source | — | 705,196,000Source | 466,486,000Source | — | 657,561,000Source | 463,018,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -159,574,000Source | -57,943,000Source | -262,183,000Source | -129,297,000Source | -193,428,000Source | -220,977,000Source | -104,723,000Source | -190,750,000Source | -189,157,000Source | -83,724,000Source | -188,741,000Source | -183,402,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 185,000Source | — | -1,703,000Source | -27,000Source | — | -480,000Source | -6,000Source | — | 546,000Source | -41,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 486,791,000Source | 342,368,000Source | 1,114,549,000Source | 343,642,000Source | -28,981,000Source | 486,720,000Source | 364,725,000Source | -7,059,000Source | 471,930,000Source | 382,221,000Source | 37,020,000Source | 41,673,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | — | 225,987,000Source | — | — | 225,861,000Source | — | — | 225,747,000Source | 225,061,000Source |
| Liabilities and EquityUSD | 509,251,000Source | 414,090,000Source | 1,139,394,000Source | 357,418,000Source | 33,844,000Source | 504,480,000Source | 377,112,000Source | 36,706,000Source | 488,617,000Source | 396,019,000Source | 37,861,000Source | 43,085,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 20,967,000Source | 18,039,000Source | 22,968,000Source | 12,110,000Source | 1,271,000Source | 16,633,000Source | 11,723,000Source | 1,581,000Source | 15,374,000Source | 13,043,000Source | 637,000Source | 1,132,000Source |
| Operating Lease, Liability, CurrentUSD | 419,000Source | 146,000Source | 669,000Source | 660,000Source | 24,000Source | 680,000Source | 283,000Source | 48,000Source | 619,000Source | 213,000Source | 76,000Source | 103,000Source |
| Accounts Payable, CurrentUSD | — | — | — | — | 571,000Source | — | — | 529,000Source | — | — | 362,000Source | 334,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,493,000Source | 842,000Source | 1,877,000Source | 1,666,000Source | 0Source | 1,127,000Source | 664,000Source | 0Source | 1,313,000Source | 755,000Source | 204,000Source | 280,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 6,968,000Source | 4,883,000Source | 24,240,000Source | 14,919,000Source | 686,000Source | 556,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | — | — | 28,000Source | -783,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -23,578,000Source | -20,869,000Source | -88,210,000Source | -57,837,000Source | -5,014,000Source | -10,912,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -14,437,000Source | 42,866,000Source | -96,745,000Source | -330,127,000Source | 0Source | -2,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 73,000Source | 13,000Source | 209,000Source | 189,000Source | 0Source | 2,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 40,600,000Source | — | 170,315,000Source | 449,539,000Source | 0Source | — |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 227,953,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | -5,014,000Source | -10,914,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 91,253,000Source | 410,875,000Source | 268,470,000Source | 65,396,000Source | 15,121,000Source | 49,520,000Source | 83,572,000Source | 46,935,000Source | 61,575,000Source | 37,431,000Source | 42,445,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | 10,165,000Source | 9,001,000Source | 7,284,000Source | 5,077,000Source | 683,000Source | 6,968,000Source | 4,883,000Source | 24,240,000Source | 14,919,000Source | 686,000Source | 556,000Source |
| DepreciationUSD | — | — | — | — | — | — | 43,000Source | 16,000Source | 83,000Source | 27,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | -5,000Source |
| General and Administrative ExpenseUSD | — | 5,117,000Source | 3,758,000Source | 6,850,000Source | 4,342,000Source | 2,820,000Source | 7,289,000Source | 5,161,000Source | 21,411,000Source | 13,063,000Source | 6,283,000Source | 5,847,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | — | — | — | — | — | — | — | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 504,000Source | — | — | 750,000Source | — | — | — | 1,468,000Source | — | — |
| Investment Income, InterestUSD | — | 3,832,000Source | 1,330,000Source | 8,897,000Source | 3,857,000Source | — | 4,606,000Source | 4,092,000Source | 16,630,000Source | 5,863,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | -30,277,000Source | -28,623,000Source | -41,206,000Source | -24,574,000Source | -22,243,000Source | -31,820,000Source | -20,999,000Source | -105,433,000Source | -83,724,000Source | -5,339,000Source | -9,926,000Source |
| Nonoperating Income (Expense)USD | — | 3,828,000Source | 826,000Source | 8,901,000Source | 3,855,000Source | -750,000Source | 4,614,000Source | 4,087,000Source | 16,618,000Source | 4,399,000Source | — | — |
| Operating ExpensesUSD | — | 34,105,000Source | 29,449,000Source | 50,107,000Source | 28,429,000Source | 21,493,000Source | 36,434,000Source | 25,086,000Source | 122,051,000Source | 88,123,000Source | 7,296,000Source | 10,596,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 200,000Source | 300,000Source | — | 200,000Source | 100,000Source | 900,000Source | 127,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 826,000Source | 4,000Source | -2,000Source | — | 8,000Source | -5,000Source | -12,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 1,698,000Source | — | 671,000Source | 54,000Source | — | — |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | —Source | —Source | — | —Source | —Source | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Operating Income (Loss)USD | — | -34,105,000Source | -29,449,000Source | -50,107,000Source | -28,429,000Source | -21,493,000Source | -36,434,000Source | -25,086,000Source | -122,051,000Source | -88,123,000Source | -7,296,000Source | -10,596,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 826,000Source | 4,000Source | -2,000Source | — | 8,000Source | -5,000Source | -12,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -105,433,000Source | -83,724,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | — | — | — | — | — | — | — | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | -30,277,000Source | -28,623,000Source | -41,206,000Source | -24,574,000Source | -22,243,000Source | -31,820,000Source | -20,999,000Source | -105,433,000Source | -83,724,000Source | -5,339,000Source | -9,926,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.46Source | — | -0.46Source | -6.96Source | — | -0.4Source | — | -3.87Source | -0.37Source | -0.69Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.46Source | — | -0.46Source | -6.96Source | — | -0.4Source | — | -3.87Source | -0.37Source | -0.69Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 15,013,655Source | — | 42,095,951Source | 3,197,975Source | — | 41,679,560Source | — | 16,789,362Source | 14,415,877Source | 14,410,143Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 15,013,655Source | — | 42,095,951Source | 3,197,975Source | — | 41,679,560Source | — | 16,789,362Source | 14,415,877Source | 14,410,143Source |
| Interest Expense (non-operating)USD | — | — | 504,000Source | — | — | 750,000Source | — | — | — | 1,468,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | — | 15,000Source | 20,000Source |
| General and Administrative ExpenseUSD | — | 5,117,000Source | 3,758,000Source | 6,850,000Source | 4,342,000Source | 2,820,000Source | 7,289,000Source | 5,161,000Source | 21,411,000Source | 13,063,000Source | 6,283,000Source | 5,847,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -105,433,000Source | -83,724,000Source | — | — |
| Interest and Other IncomeUSD | — | — | — | — | — | 444,000Source | — | — | — | — | 1,957,000Source | 675,000Source |
| Investment Income, InterestUSD | — | 3,832,000Source | 1,330,000Source | 8,897,000Source | 3,857,000Source | — | 4,606,000Source | 4,092,000Source | 16,630,000Source | 5,863,000Source | — | — |
| Nonoperating Income (Expense)USD | — | 3,828,000Source | 826,000Source | 8,901,000Source | 3,855,000Source | -750,000Source | 4,614,000Source | 4,087,000Source | 16,618,000Source | 4,399,000Source | — | — |
| Operating ExpensesUSD | — | 34,105,000Source | 29,449,000Source | 50,107,000Source | 28,429,000Source | 21,493,000Source | 36,434,000Source | 25,086,000Source | 122,051,000Source | 88,123,000Source | 7,296,000Source | 10,596,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 200,000Source | 300,000Source | — | 200,000Source | 100,000Source | 900,000Source | 127,000Source | — | — |
| Other ExpensesUSD | — | 9,600,000Source | 13,400,000Source | — | 4,200,000Source | 15,400,000Source | — | 1,500,000Source | — | 42,000,000Source | — | — |
| Research and Development ExpenseUSD | — | 28,988,000Source | 25,691,000Source | 43,257,000Source | 24,087,000Source | 18,673,000Source | 29,145,000Source | 19,925,000Source | 100,640,000Source | 75,060,000Source | 1,013,000Source | 4,749,000Source |
Offerings
Registration 333-298488
Registration 333-294852
Filing attachments
ea030959401ex99-1.htm · 8-K · 2026-10-26
Exhibit 99.1 Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance into Phase 3 trials in 1H 2027 52-week EVERLAST-A results on track for December 2026 ORKA-002 16-week results from ORCA-SURGE Phase …
Read attachment ↗ea030959401ex99-2.htm · 8-K · 2026-10-26
Exhibit 99.2 ©2026 Oruka Therapeutics ©2026 ORUKA THERAPEUTICS EVERLAST - B Interim Data ORKA - 001 Phase 2b trial in psoriasis October 26, 2026 ©2026 Oruka Therapeutics 2 Disclaimers The information contained in this presentation has been prepared by Oruka Therapeutics, Inc. (the “Company”) and pertains to the business and operations of the Company. The information: (a) is provided as of the date hereof, is subject to change without notice, and is based on publicly available information, i nt…
Read attachment ↗ea030131201ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ea030131201ex99-1.htm PRESS RELEASE, DATED AUGUST 10, 2026 Exhibit 99.1 Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program for ORKA-001 expected to begin in 1H 2027 ORCA-SURGE Week 16 data accelerated, now expected in …
Read attachment ↗ea028846101ex99-1.htm · 8-K · 2026-04-30
EX-99.1 4 ea028846101ex99-1.htm EXCERPT FROM PRELIMINARY PROSPECTUS SUPPLEMENT DATED APRIL 27, 2026 Exhibit 99.1 Recent Developments Certain Financial and Operating Data for First Quarter 2026 While we have not finalized our full financial results for the quarter ended March 31, 2026, we estimate that our cash, cash equivalents, and investments were approximately $496 million as of March 31, 2026. This preliminary estimate is based on currently available information and is subject to rev…
Read attachment ↗ea028778201ex99-1.htm · 8-K · 2026-04-27
EX-99.1 2 ea028778201ex99-1.htm PRESS RELEASE, DATED APRIL 27, 2026 Exhibit 99.1 Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to …
Read attachment ↗ea028778201ex99-2.htm · 8-K · 2026-04-27
EX-99.2 3 ea028778201ex99-2.htm PRESENTATION, DATED APRIL 27, 2026 Exhibit 99.2 ©2026 Oruka Therapeutics ©2026 ORUKA THERAPEUTICS EVERLAST - A Interim Data ORKA - 001 Phase 2a trial in psoriasis April 27, 2026 ©2026 Oruka Therapeutics 2 Disclaimers The information contained in this presentation has been prepared by Oruka Therapeutics, Inc. (the “Company”) and contains inf orm ation pertaining to the business and operations of the Company. The information contained in this presentation: (a)…
Read attachment ↗